Sara Eisen is a CNBC anchor and host of “Squawk on the Street” and “Money Movers.” This week, world leaders are descending on Washington for the semiannual meetings of the International Monetary Fund ...

Part of a pharmaceutical factory which opened more than 75 years ago will be demolished. GSK plc (formerly GlaxoSmithKline) ended its Cumbria operations earlier this year at its Ulverston site, after ...

Eli Lilly's weight-loss drug Mounjaro is rapidly climbing the ranks in the Indian pharmaceutical market, nearing GlaxoSmithKline's antibiotic Augmentin in monthly sales. Launched in March, Mounjaro ...

Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. GlaxoSmithKline ( (GB:GSK)) has shared an ...

GSK said Emma Walmsley would step down after more than eight years as chief executive and named its commercial chief, Luke Miels, to succeed her in the top job. Walmsley, who became CEO of the U.K.

(Reuters) -GSK's CEO Emma Walmsley will step down at the end of the year and be replaced by insider Luke Miels, the drugmaker said on Monday, a surprise switch as the British firm looks to rev up its ...

The Trump administration is touting an old generic drug as a new treatment for autism despite limited evidence, sparking unease among doctors and scientists who say the medication needs to be studied ...

(Reuters) -On Monday, the U.S. Food and Drug Administration published a notice to the Federal Register ahead of a speech by President Donald Trump, approving a version of leucovorin made by ...

The U.S. Food and Drug Administration has approved a version of leucovorin made by GlaxoSmithKline, years after the company pulled the drug from consideration when it stopped manufacturing it. The ...

Emerging markets are increasingly important for multinational companies (MNCs), but entering these markets can be a difficult and costly experience. As interest in emerging markets grows, so too has ...

(Reuters) - Drugmaker GSK said Wednesday it would invest $30 billion in U.S. research and development and supply chain infrastructure over five years, after U.S. President Donald Trump arrived in ...